Synordia: Withdrawal of the marketing authorisation application
On 7 December 2006, Fournier Laboratories Ireland Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a marketing authorisation for Synordia, for the improvement of glycaemic control and dyslipidaemia in patients with type 2 diabetes.
|Date of withdrawal||
|Company making the application|
Fournier Laboratories withdraws its marketing authorisation application for Synordia (PDF/25.25 KB)
First published: 08/12/2006
Last updated: 08/12/2006
Withdrawal letter : Synordia (PDF/17.54 KB)
First published: 07/12/2006
Last updated: 07/12/2006
Questions and answers on the withdrawal of the marketing application for Synordia (PDF/42.41 KB)
First published: 14/12/2006
Last updated: 14/12/2006
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').